Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Moat Score: 0/10 (As of Jul. 11, 2026)


FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
77 GF Score
Price €5.70
GF Value €3.30
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co Moat Score?

Biocytogen Pharmaceuticals (Beijing) Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Biocytogen Pharmaceuticals (Beijing) Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Biocytogen Pharmaceuticals (Beijing) Co might have No Moat - No discernible moat.

Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Biocytogen Pharmaceuticals (Beijing) Co Moat Score Related Terms

FRA:I54
77GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €5.70 is trading 72.7% above its estimated GF Value™ of €3.30. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.

Key valuation signals for FRA:I54:

  • Moat Score: 0
  • GF Value™: €3.30 vs. price of €5.70 (72.7% above fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
77GF Score

Get the complete analysis for FRA:I54

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.70
Price
€3.30
GF Value